Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $446.55 | 11 | 54.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $300.00 | 1 | 36.7% |
| Education | $69.99 | 1 | 8.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $310.84 | 2 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $157.47 | 2 | $0 (2017) |
| Relypsa, Inc. | $106.01 | 1 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $69.99 | 1 | $0 (2018) |
| Veloxis Pharmaceuticals, Inc. | $62.31 | 2 | $0 (2019) |
| Horizon Therapeutics plc | $42.11 | 2 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $26.35 | 1 | $0 (2023) |
| Alexion Pharmaceuticals, Inc. | $20.89 | 1 | $0 (2019) |
| Genentech USA, Inc. | $20.57 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $26.35 | 1 | Takeda Pharmaceuticals U.S.A., Inc. ($26.35) |
| 2022 | $42.11 | 2 | Horizon Therapeutics plc ($42.11) |
| 2019 | $160.59 | 3 | Relypsa, Inc. ($106.01) |
| 2018 | $380.83 | 3 | GENZYME CORPORATION ($310.84) |
| 2017 | $206.66 | 4 | Novartis Pharmaceuticals Corporation ($157.47) |
All Payment Transactions
13 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2023 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Food and Beverage | In-kind items and services | $26.35 | General |
| Category: IMMUNOLOGY | ||||||
| 06/01/2022 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $21.99 | General |
| Category: KRYSTEXXA | ||||||
| 05/04/2022 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $20.12 | General |
| Category: KRYSTEXXA | ||||||
| 09/11/2019 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Drug) | Food and Beverage | In-kind items and services | $20.89 | General |
| Category: Immunology | ||||||
| 07/18/2019 | Veloxis Pharmaceuticals, Inc. | Envarsus (Drug), Envarsus | Food and Beverage | In-kind items and services | $33.69 | General |
| Category: Immunosuppressant | ||||||
| 05/29/2019 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $106.01 | General |
| Category: Hyperkalemia | ||||||
| 11/08/2018 | GENZYME CORPORATION | THYMOGLOBULIN (Drug) | Food and Beverage | In-kind items and services | $10.84 | General |
| Category: ONCOLOGY | ||||||
| 09/12/2018 | SANOFI-AVENTIS U.S. LLC | JEVTANA (Drug) | Education | In-kind items and services | $69.99 | General |
| Category: ONCOLOGY | ||||||
| 06/18/2018 | GENZYME CORPORATION | THYMOGLOBULIN (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2017 | Novartis Pharmaceuticals Corporation | ZORTRESS (Drug) | Food and Beverage | In-kind items and services | $39.39 | General |
| Category: IMMUNOLOGY | ||||||
| 10/30/2017 | Genentech USA, Inc. | Rituxan (Biological) | Food and Beverage | In-kind items and services | $20.57 | General |
| Category: BioOncology/Immunology | ||||||
| 06/29/2017 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $118.08 | General |
| 03/30/2017 | Veloxis Pharmaceuticals, Inc. | Envarsus XR (Drug), Envarsus XR, Envarsus XR | Food and Beverage | In-kind items and services | $28.62 | General |
| Category: Immunosuppressant | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 793 | 1,251 | $466,312 | $119,968 |
| 2022 | 9 | 721 | 1,277 | $483,629 | $122,052 |
| 2021 | 12 | 599 | 1,031 | $407,784 | $111,501 |
| 2020 | 9 | 610 | 1,110 | $391,567 | $102,056 |
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 228 | 425 | $197,960 | $50,599 | 25.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 74 | 195 | $70,135 | $19,894 | 28.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 180 | 241 | $77,374 | $18,439 | 23.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 65 | 113 | $27,202 | $7,598 | 27.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 50 | 51 | $31,446 | $7,512 | 23.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 39 | 42 | $17,829 | $4,564 | 25.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 38 | 39 | $14,024 | $3,812 | 27.2% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 48 | 69 | $9,678 | $2,919 | 30.2% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 40 | 44 | $13,724 | $2,903 | 21.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 31 | 32 | $6,940 | $1,728 | 24.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 248 | 443 | $209,867 | $51,470 | 24.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 90 | 301 | $99,319 | $26,151 | 26.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 193 | 282 | $90,101 | $22,830 | 25.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 40 | 41 | $26,172 | $6,614 | 25.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 44 | 89 | $20,449 | $5,400 | 26.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 44 | 47 | $16,075 | $4,198 | 26.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 23 | 23 | $9,995 | $2,648 | 26.5% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 24 | 27 | $8,680 | $1,956 | 22.5% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 15 | 24 | $2,971 | $784.56 | 26.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 248 | 516 | $221,457 | $64,588 | 29.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 86 | 215 | $72,146 | $18,994 | 26.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 45 | 45 | $29,179 | $7,790 | 26.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 42 | 68 | $15,868 | $4,224 | 26.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 45 | 49 | $13,812 | $3,556 | 25.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 24 | 26 | $11,528 | $2,936 | 25.5% |
About Dr. Alice Peng, M.D
Dr. Alice Peng, M.D is a Internal Medicine healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790712305.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alice Peng, M.D has received a total of $816.54 in payments from pharmaceutical and medical device companies, with $26.35 received in 2023. These payments were reported across 13 transactions from 9 companies. The most common payment nature is "Food and Beverage" ($446.55).
As a Medicare-enrolled provider, Peng has provided services to 2,723 Medicare beneficiaries, totaling 4,669 services with total Medicare billing of $455,577. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Nephrology
- Location Los Angeles, CA
- Active Since 06/27/2006
- Last Updated 08/21/2014
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1790712305
Products in Payments
- THYMOGLOBULIN (Drug) $310.84
- Veltassa (Drug) $106.01
- JEVTANA (Drug) $69.99
- KRYSTEXXA (Biological) $42.11
- ZORTRESS (Drug) $39.39
- Envarsus (Drug) $33.69
- Envarsus XR (Drug) $28.62
- LIVTENCITY (Drug) $26.35
- SOLIRIS (Drug) $20.89
- Rituxan (Biological) $20.57
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Los Angeles
Dr. Thomas Magee, Md, MD
Internal Medicine — Payments: $1.2M
Dr. Julio Gutierrez, Md, MD
Internal Medicine — Payments: $920,439
Dr. Mohammad Kamgar, M.d, M.D
Internal Medicine — Payments: $471,176
Dr. Caroline Piatek, M.d,, M.D,
Internal Medicine — Payments: $468,526
Gottfried Konecny, Md, MD
Internal Medicine — Payments: $399,651
Dr. Elizabeth Volkmann, Md, MD
Internal Medicine — Payments: $397,666